Baxter Supports New Study Showing Blood Purification with ... | 合法醫療器材資訊網

2020年10月27日—TheOxirisSetisauthorizedforusefornolongerthanthedurationoftheCOVID-19publichealthemergencyandhasneitherbeenclearedor ...

PDF[1]

DEERFIELD, Ill. - 2020-10-27

Baxter International Inc. (NYSE:BAX), a global leader in acute care, recognizes the findings of a prospective, multicenter, observational study on data from the OxirisNet Registry evaluating severely ill patients with COVID-19 in Italy treated with extracorporeal (outside the body) blood purification (EBP) using the company’s Oxiris filter set. From the study, recently published in Critical Care[2], the investigators reported that patients experienced a significant reduction in serum IL-6 (a pro-inflammatory cytokine) levels, improvement in indicators of organ dysfunction and reduction in expected intensive care unit (ICU) mortality rate as compared to a historical control. Due to the study design, the results do not provide evidence of a causal relationship between EBP treatment with Oxiris and these outcomes. The results do, h...